Aims Antithrombotic secondary prevention in stable cardiovascular disease (SCVD) patients
at high ischemic risk remains unclear. We compared the efficacy and safety of aspirin …

Backgroud: Antithrombotic secondary prevention in stable cardiovascular disease (SCVD)
patients at high ischemic risk remains unclear. We compared aspirin monotherapy; …

Objective The aim of this study was to evaluate the efficacy and safety of antithrombotic
regimens and their combinations in preventing thrombotic incidents in patients with stable …

Background Nine oral antithrombotic medications currently available in the United States
and Europe have been studied in clinical trials for secondary prevention of cardiac events …

Abstract Purpose of Review Stable and unstable ischemic heart disease are a growing
component in all facets of healthcare, including ER visits, hospitalizations, and financial …

Aims To appraise all available antithrombotic treatments within or after 12 months following
coronary revascularization and/or acute coronary syndrome in two network meta-analyses …

In patients with stable atherosclerotic vascular disease, the combination of a low dose of
rivaroxaban and aspirin is associated with a lower rate of cardiovascular outcomes but more …

Background Long‐term antithrombotic strategies for patients with chronic coronary
syndrome with high‐risk factors represent an important treatment dilemma in clinical …

Background Aspirin therapy significantly lowers the risk of cardiovascular (CV) events.
Combining aspirin with low dose rivaroxaban (2.5 mg twice daily) may yield a significant …

Background Although acetylsalicylic acid is the most commonly used antithrombotic agent
for the secondary prevention of cardiovascular events, residual atherothrombotic risk has …